Paragon Health Institute Icon White

The High Cost of Constant Covid Testing

Shutterstock 1700465836 Smaller 10
Public Advisor
Ge Bai, PhD, CPA, is a Professor of Accounting at the Johns Hopkins Carey Business School and Professor of Health Policy & Management at the Johns Hopkins Bloomberg School of Public Health. In 2022, she became a Visiting Scholar at the Congressional Budget Office.

Testing labs in the U.S. have been earning windfall profits as a direct consequence of the Covid-19 pandemic. Using tax data from Hawaii, we found that statewide growth in private diagnostic labs’ monthly revenue tracked the volume of Covid-19 PCR tests in lockstep. Between May and December 2020, lab revenue grew at an average of 8% a month. Labs are making more than $10 a test in profit.

Why are these profits possible? The American healthcare system let labs set prices for Covid-19 tests well above their costs, costing taxpayers and private insurance companies dearly, for three reasons.

First, reimbursement rates set by Medicare and Medicaid fail to account for economies of scale. When labs do more tests, their unit cost drops, but reimbursement rates stay fixed. Labs with a high testing volume can perform a PCR test for less than $20, but the Medicare payment rate remains $51. (Medicaid can pay even more.) Medicare reimbursement rates often serve as a floor when private insurers negotiate with providers. As a result, the high and static government-set rates give providers leverage to demand higher payments.

The full article can be found in The Wall Street Journal.

Related Content


Sign up now for your health policy updates.

This field is for validation purposes and should be left unchanged.